Key facts
- BioIntelliSense’s last known valuation is $1.2B (Dec 2022).
- It has raised $318.6M across 4 recorded rounds; the latest was Later Stage VC ($58.3M) in Dec 2025.
- Notable investors include Chimera Capital, TLG Capital Management, Mary Tolan, Confluent, Dexcom Ventures — 18 tracked in total.
- BioIntelliSense has filed 4 Form Ds with the SEC since 2020, most recently Dec 2025 ($58.1M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for BioIntelliSense
Funding rounds
4 roundsAbout BioIntelliSense
Developer of a remote patient monitoring device designed to enhance healthcare delivery. The company's device provides continuous, passive monitoring of vital signs and biometrics through medical-grade wearable devices with actionable health insights and supporting early intervention, enabling healthcare providers to improve patient outcomes, streamline clinical workflows and reduce hospital readmissions.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2019
- Employees
- 102
- Website
- biointellisense.com/
- Ownership
- Privately Held (backing)
BioIntelliSense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioIntelliSense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioIntelliSense in its N-PORT filings yet. We sweep new filings monthly.